Allianz Asset Management’s Summit Therapeutics SMMT Stock Holding History

Allianz Asset Management’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$434K	Buy	29,800 +7,600	+34%	+$135K	﹤0.01%	2010
2026 Q1	$421K	Hold	22,200	–	–	﹤0.01%	1859
2025 Q4	$388K	Hold	22,200	–	–	﹤0.01%	1868
2025 Q3	$459K	Sell	22,200 -7,600	-26%	-$184K	﹤0.01%	1860
2025 Q2	$634K	Sell	29,800 -13,061	-30%	-$298K	﹤0.01%	1774
2025 Q1	$827K	Sell	42,861 -1,939	-4%	-$38.9K	﹤0.01%	1728
2024 Q4	$799K	Sell	44,800 -13,937	-24%	-$270K	﹤0.01%	1709
2024 Q3	$1.29M	Buy	58,737 +38,784	+194%	+$542K	﹤0.01%	1555
2024 Q2	$156K	Buy	+19,953	New	+$108K	﹤0.01%	2043

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Allianz Asset Management's SMMT Position: Q2 2026 in Review

Allianz Asset Management increased its Summit Therapeutics (SMMT) stake by 34% in Q2 2026, buying an estimated $135K and bringing the position to 29,800 shares worth $434K. The position accounts for ﹤0.01% of the portfolio, ranked #2010.

Allianz Asset Management first reported a position in SMMT in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.29M in Q3 2024. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Allianz Asset Management held 29,800 shares of Summit Therapeutics worth $434K as of Q2 2026.
Allianz Asset Management bought 7,600 Summit Therapeutics shares in Q2 2026, an estimated $135K.
Summit Therapeutics made up ﹤0.01% of Allianz Asset Management's portfolio in Q2 2026, its #2010 holding.
Allianz Asset Management first reported a position in Summit Therapeutics in Q2 2024 and has held it in 9 quarters since.
Allianz Asset Management's Summit Therapeutics position peaked at $1.29M in Q3 2024.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Allianz Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.